- Home
- AEE vs BIIB Comparison
AEE vs BIIB Comparison
Compare AEE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEE
- BIIB
- Stock Information
- Founded
- AEE 1901
- BIIB 1978
- Country
- AEE United States
- BIIB United States
- Employees
- AEE N/A
- BIIB N/A
- Industry
- AEE Power Generation
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- AEE Utilities
- BIIB Health Care
- Exchange
- AEE Nasdaq
- BIIB Nasdaq
- Market Cap
- AEE 25.3B
- BIIB 25.1B
- IPO Year
- AEE N/A
- BIIB 1991
- Fundamental
- Price
- AEE $91.18
- BIIB $156.46
- Analyst Decision
- AEE Buy
- BIIB Buy
- Analyst Count
- AEE 13
- BIIB 26
- Target Price
- AEE $86.45
- BIIB $255.29
- AVG Volume (30 Days)
- AEE 1.3M
- BIIB 1.5M
- Earning Date
- AEE 11-06-2024
- BIIB 10-30-2024
- Dividend Yield
- AEE 2.94%
- BIIB N/A
- EPS Growth
- AEE N/A
- BIIB 10.05
- EPS
- AEE 4.26
- BIIB 11.06
- Revenue
- AEE $7,058,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- AEE $5.37
- BIIB N/A
- Revenue Next Year
- AEE $5.63
- BIIB N/A
- P/E Ratio
- AEE $21.42
- BIIB $14.14
- Revenue Growth
- AEE N/A
- BIIB N/A
- 52 Week Low
- AEE $67.03
- BIIB $153.62
- 52 Week High
- AEE $95.69
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- AEE 49.16
- BIIB 31.68
- Support Level
- AEE $91.47
- BIIB $158.44
- Resistance Level
- AEE $93.04
- BIIB $162.62
- Average True Range (ATR)
- AEE 1.25
- BIIB 3.35
- MACD
- AEE -0.41
- BIIB 0.74
- Stochastic Oscillator
- AEE 5.05
- BIIB 24.34
About AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves more than 2.4 million electricity customers and more than 900,000 natural gas customers.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.